UCB Cuts 2.1 Billion Deal to Acquire Ra Pharma

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
Source: The Scientist - Category: Science Tags: News & Opinion Source Type: news